Every 8-K that Immunocore Holdings plc (IMCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IMCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMCR filings page.
Immunocore Holdings plc (IMCR) reports that it has achieved target enrollment of 540 patients in its global, randomized, registrational Phase 3 TEBE-AM trial of KIMMTRAK (tebentafusp) as monotherapy and in combination with pembrolizumab versus Investigator’s Choice in HLA-A*02:01-positive advanced melanoma after prior therapy. The primary endpoint is overall survival, and the company expects to share topline overall survival data as early as the end of 2026. KIMMTRAK, developed from Immunocore’s ImmTAC TCR bispecific platform, is already approved for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in multiple major markets.
Immunocore Holdings reported Q2 2026 KIMMTRAK net product revenue of $115.9 million, up 18% year over year, with sales of $74.9 million in the US, $34.1 million in Europe and $6.9 million in international markets. Net loss narrowed to $0.8 million in the quarter, and the company generated $12.2 million net income for the first half of 2026.
R&D spending was $73.9 million in Q2 as three Phase 3 studies advanced. Cash, cash equivalents and marketable securities totaled $880.2 million as of June 30, 2026, compared with $864.2 million at year-end 2025; the company expects to pay about $120 million in sales-related rebate accruals in the second half of 2026.
Five-year data from the Phase 3 KIMMTRAK trial in metastatic uveal melanoma showed overall survival of 16% at five years versus 8% for control, with median overall survival of 21.6 vs 16.9 months. Enrollment is nearing completion in the Phase 3 TEBE-AM trial in previously treated cutaneous melanoma, the PRISM-MEL-301 Phase 3 trial is enrolling first-line cutaneous melanoma patients, and the pipeline also includes PRAME-targeting brenetafusp studies, an HIV program (IMC‑M113V) and autoimmune candidates such as IMC‑S118AI.
Immunocore Holdings plc reported the results of its 2026 Annual General Meeting of Shareholders. All ten resolutions proposed at the meeting were approved on a poll.
Shareholders re-appointed directors Siddharth Kaul, William Pao, M.D., Ph.D., and Kristine Peterson. They also approved, on an advisory basis, the compensation of named executive officers and the directors’ remuneration report for the year ended December 31, 2025.
Deloitte LLP was ratified as the Company’s U.S. independent registered public accounting firm for the year ending December 31, 2026 and re-appointed as U.K. statutory auditors, with the audit committee authorized to set their remuneration. Shareholders received and adopted the 2025 U.K. statutory annual accounts and reports and authorized the Company to make political donations or incur political expenditure.
Immunocore Holdings plc reported first-quarter 2026 results, led by KIMMTRAK net product revenue of $106.7 million, up from $93.9 million a year earlier, driven by higher volumes in the United States and Europe and broader global reach.
The company generated net income of $13.0 million, compared with $5.0 million in Q1 2025, with diluted earnings per share rising to $0.25 from $0.10. Cash, cash equivalents and marketable securities totaled $844.9 million as of March 31, 2026, supporting an extensive pipeline that includes multiple Phase 3 oncology trials, a Phase 1/2 HIV program, and early-stage autoimmune candidates built on its ImmTAX TCR bispecific platform.
Immunocore Holdings reported strong 2025 growth from its lead therapy KIMMTRAK while remaining modestly loss-making. KIMMTRAK net sales reached $400.0 million for 2025, up from $310.0 million in 2024, with Q4 2025 sales of $104.5 million versus $84.1 million a year earlier.
Full-year net loss narrowed to $35.5 million from $51.1 million, or $0.71 per share versus $1.02. The company increased investment in its pipeline, with 2025 R&D expenses of $274.9 million and SG&A of $165.4 million. Cash, cash equivalents and marketable securities were $864.2 million as of December 31, 2025.
Management highlighted 15 consecutive quarters of KIMMTRAK revenue growth and ongoing global launches in uveal melanoma, while advancing multiple Phase 3 trials in melanoma, PRAME-targeted programs in solid tumors, an HIV functional cure program, and first autoimmune candidates, with key data readouts anticipated in the second half of 2026.
Immunocore Holdings plc announced that David Berman has decided to resign as Head of Research & Development, effective February 27, 2026, to pursue another opportunity. The company states that his resignation is not due to any disagreement over operations, policies, or practices.
Immunocore does not plan to appoint a direct replacement for Dr. Berman and instead intends to streamline and leverage its existing R&D structure. This signals a leadership transition within the research organization while maintaining continuity through the current R&D framework.
Immunocore Holdings plc reported a preliminary estimate of its cash, cash equivalents and marketable securities of about $864 million as of December 31, 2025. This figure is based on internal estimates, is unaudited and may change once full year-end financial statements are completed, and any adjustments identified by the company or its independent auditors could be material.
The company also outlined its strategic priorities for 2026 in a press release and updated its corporate presentation with business and strategy updates, including materials to be used at the 44th Annual J.P. Morgan Healthcare Conference. In addition, Immunocore published an updated pipeline chart for KIMMRAK (tebentafusp) and its development-stage therapeutic candidates. These materials are provided as exhibits and, where noted, are furnished rather than filed under securities law.
Immunocore Holdings plc furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025, along with recent corporate updates.
The press release is included as Exhibit 99.1 and is incorporated by reference. The materials under Item 2.02 are being furnished, not filed, and therefore are not subject to Section 18 liabilities of the Exchange Act or automatically incorporated into other SEC filings.